Results 211 to 220 of about 682,776 (395)

Recurrence Risk in Pediatric Noninfectious Uveitis During Adalimumab Tapering: An International Multicenter Retrospective Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective This study aims to assess the risk of noninfectious uveitis (NIU) relapse in pediatric patients undergoing adalimumab (ADA) tapering, evaluating potential predictors of such risk. Methods We conducted a multicenter retrospective cohort study involving pediatric patients with NIU who underwent ADA tapering due to inactive uveitis.
Achille Marino   +31 more
wiley   +1 more source

Report on Ophthalmology [PDF]

open access: yesThe Boston Medical and Surgical Journal, 1872
openaire   +2 more sources

Genetics in Ophthalmology [PDF]

open access: yesJournal of Ophthalmology, 2018
Lev Prasov   +4 more
openaire   +3 more sources

Virtual Ophthalmology: Telemedicine in a COVID-19 Era

open access: yesAmerican journal of ophthalmology-glaucoma, 2020
Sophia M Saleem   +3 more
semanticscholar   +1 more source

A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis

open access: yesArthritis &Rheumatology, Accepted Article.
Background Individuals with serum elevations of anti‐cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such ‘at‐risk’ individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence.
Kevin D. Deane   +33 more
wiley   +1 more source

Podcasts in health education—Insights from a scoping review and survey

open access: yesAnatomical Sciences Education, EarlyView.
Abstract Podcasts have rapidly emerged as a powerful tool for health communication, especially since the COVID‐19 pandemic. While evidence shows that podcasts can enhance student knowledge, confidence, and flexibility in learning, their educational impact is primarily studied within formal academic contexts.
Matthew J. Barton   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy